We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? [Letter].
- Authors
Silva, Vinicius Trindade Gomes da; Gebrin, Thiago; Paiva, Wellingson Silva
- Abstract
Bevacizumab for the Treatment of High-Grade Meningiomas: Is There New Evidence? There is a controversy regarding Simpson III, which is usually considered as gross total resection.[1] Indeed, there is a large difference between grades III and IV, considering the volume of residual tumor. Mainly for the meningioma grade III treatment, pharmacotherapy can be considered; however, it is still evidence level IV.[1] Bevacizumab is an anti-angiogenic therapy, a monoclonal antibody that binds to the VEGF-A isoforms and thereby inhibits the activation of VEGF signaling pathways, avoiding neovascularization.[2] It is a promising medication for non-benign meningiomas.
- Subjects
BEVACIZUMAB; NEOVASCULARIZATION inhibitors; THERAPEUTICS; PROGRESSION-free survival; SKULL tumors
- Publication
Neuropsychiatric Disease & Treatment, 2022, Vol 18, p2453
- ISSN
1176-6328
- Publication type
Letter to the Editor
- DOI
10.2147/NDT.S392309